AR011607A1 - Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar - Google Patents

Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar

Info

Publication number
AR011607A1
AR011607A1 ARP980100442A ARP980100442A AR011607A1 AR 011607 A1 AR011607 A1 AR 011607A1 AR P980100442 A ARP980100442 A AR P980100442A AR P980100442 A ARP980100442 A AR P980100442A AR 011607 A1 AR011607 A1 AR 011607A1
Authority
AR
Argentina
Prior art keywords
cancer
tumor suppressor
gene
tumor
isolated
Prior art date
Application number
ARP980100442A
Other languages
English (en)
Spanish (es)
Original Assignee
Univ Texas
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25152739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011607(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas, Myriad Genetics Inc filed Critical Univ Texas
Publication of AR011607A1 publication Critical patent/AR011607A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ARP980100442A 1997-01-30 1998-01-30 Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar AR011607A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/791,115 US6262242B1 (en) 1997-01-30 1997-01-30 Tumor suppressor designated TS10Q23.3

Publications (1)

Publication Number Publication Date
AR011607A1 true AR011607A1 (es) 2000-08-30

Family

ID=25152739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100442A AR011607A1 (es) 1997-01-30 1998-01-30 Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar

Country Status (14)

Country Link
US (1) US6262242B1 (https=)
EP (2) EP0972024B2 (https=)
JP (5) JP2001511002A (https=)
AR (1) AR011607A1 (https=)
AT (1) ATE499444T1 (https=)
AU (1) AU745296B2 (https=)
CA (1) CA2278849C (https=)
DE (1) DE69842141D1 (https=)
DK (1) DK0972024T4 (https=)
ES (1) ES2361044T5 (https=)
IL (1) IL131168A0 (https=)
PT (1) PT972024E (https=)
WO (1) WO1998033907A1 (https=)
ZA (1) ZA98756B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287854B1 (en) 1996-10-22 2001-09-11 Imperial Cancer Research Technology Limited Diagnosis of susceptibility to cancer and treatment thereof
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
AU6653698A (en) * 1997-02-07 1998-08-26 Trustees Of Columbia University In The City Of New York, The Use of the p-ten suppressor gene in diagnosis and treatment of cancer
US6861256B2 (en) 1997-05-15 2005-03-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
US6225120B1 (en) 1997-05-15 2001-05-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
AU8479498A (en) * 1997-07-08 1999-02-08 Cold Spring Harbor Laboratory Dual specificity phosphatase and methods of use
EP1012338B1 (en) * 1997-08-26 2005-06-15 The Board Of Regents, The University Of Texas System A tumor suppressor designated ts10q23.3
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
EP1463834A4 (en) * 2001-12-20 2005-08-10 Tularik Inc IDENTIFICATION OF AN AMPLIFIED GENE AND TARGET FOR A DRUG INTERVENTION
US7981618B2 (en) * 2003-11-05 2011-07-19 Board Of Regents Of The University Of Texas System Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
WO2010028288A2 (en) 2008-09-05 2010-03-11 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
EP2619329B1 (en) 2010-09-24 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
EP2798082B1 (en) 2011-12-30 2017-04-12 Abbott Molecular Inc. Materials and methods for diagnosis, prognosis and assessment of therapeutic/prophylactic treatment of prostate cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
FR2616841A1 (fr) 1987-06-17 1988-12-23 Rauner Hans Perfectionnements au systeme de bloquage en position ouverte a levier de serrage pivotant, pour fiches et paumelles de portes et de fenetres
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
ATE92538T1 (de) 1988-01-21 1993-08-15 Genentech Inc Verstaerkung und nachweis von nukleinsaeuresequenzen.
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4932207A (en) 1988-12-28 1990-06-12 Sundstrand Corporation Segmented seal plate for a turbine engine
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
NZ320425A (en) 1995-10-23 2001-03-30 Imp Cancer Res Tech Diagnosis of susceptibility to cancer using nucleic acid probes
EP1012338B1 (en) * 1997-08-26 2005-06-15 The Board Of Regents, The University Of Texas System A tumor suppressor designated ts10q23.3
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
CA2278849A1 (en) 1998-08-06
JP5202583B2 (ja) 2013-06-05
EP0972024A1 (en) 2000-01-19
EP0972024B1 (en) 2011-02-23
DK0972024T4 (da) 2014-07-07
IL131168A0 (en) 2001-01-28
DK0972024T3 (da) 2011-04-26
JP2010259438A (ja) 2010-11-18
EP2366712A2 (en) 2011-09-21
ATE499444T1 (de) 2011-03-15
JP4768783B2 (ja) 2011-09-07
PT972024E (pt) 2011-05-05
ZA98756B (en) 1998-08-25
WO1998033907A1 (en) 1998-08-06
AU745296B2 (en) 2002-03-21
DE69842141D1 (de) 2011-04-07
EP2366712A3 (en) 2012-11-14
JP2014155493A (ja) 2014-08-28
ES2361044T5 (es) 2014-10-01
ES2361044T3 (es) 2011-06-13
AU6018998A (en) 1998-08-25
JP2013128485A (ja) 2013-07-04
EP0972024B2 (en) 2014-06-25
JP2009039107A (ja) 2009-02-26
JP2001511002A (ja) 2001-08-07
US6262242B1 (en) 2001-07-17
CA2278849C (en) 2016-04-19

Similar Documents

Publication Publication Date Title
AR011607A1 (es) Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar
Holaska et al. An emerin “proteome”: purification of distinct emerin-containing complexes from HeLa cells suggests molecular basis for diverse roles including gene regulation, mRNA splicing, signaling, mechanosensing, and nuclear architecture
Soteriou et al. A survey of interactions made by the giant protein titin
Hoek et al. hnRNP A2 selectively binds the cytoplasmic transport sequence of myelin basic protein mRNA
McMahon et al. Human α spectrin II and the Fanconi anemia proteins FANCA and FANCC interact to form a nuclear complex
van Kuijk et al. Human and murine fibroblast single-cell transcriptomics reveals fibroblast clusters are differentially affected by ageing and serum cholesterol
Eguchi et al. Intracellular MMP3 promotes HSP gene expression in collaboration with chromobox proteins
EA199700447A1 (ru) Последовательность днк и кодируемый ею специфический для молочной железы белок карциномы молочной железы
Sakai et al. Novel RUNX1‐PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t (1; 21)(p36; q22)
Schneider et al. Evidence that vitronectin is a potent migration-enhancing factor for cancer cells chaperoned by fibrinogen: a novel view of the metastasis of cancer cells to low-fibrinogen lymphatics and body cavities
Yoon et al. NOTUM is involved in the progression of colorectal cancer
Lee et al. The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL
Parrish et al. Size heterogeneity, phosphorylation and transmembrane organisation of desmosomal glycoproteins 2 and 3 (desmocollins) in MDCK cells
Kolovskaya et al. DNA-aptamer/protein interaction as a cause of apoptosis and arrest of proliferation in Ehrlich ascites adenocarcinoma cells
Sommer et al. Implication of RNA-binding protein La in proliferation, migration and invasion of lymph node-metastasized hypopharyngeal SCC cells
Keon et al. Isoform specific expression of the neuronal F-actin binding protein, drebrin, in specialized cells of stomach and kidney epithelia
Goldstein et al. Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries
Wang et al. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma
Vegliante et al. NR1H3 (LXRα) is associated with pro‐inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b‐cell lymphoma
Gomersall et al. The Mycoplasma hyorhinis p37 protein rapidly induces genes in fibroblasts associated with inflammation and cancer
Shi et al. Myoferlin disturbs redox equilibrium to accelerate gastric cancer migration
Irmer et al. Syntenin Controls Extracellular Vesicle‐Induced Tumour Migration by Regulating the Expression of Adhesion Proteins on Small Extracellular Vesicles
Li et al. EPLIN-β is a novel substrate of ornithine decarboxylase antizyme 1 and mediates cellular migration
Deng et al. iTRAQ-based quantitative proteomic analysis of esophageal squamous cell carcinoma
UY24389A1 (es) Composición farmacéutica para el tratamiento de carcinoma de epitelio plano

Legal Events

Date Code Title Description
FA Abandonment or withdrawal